Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Unlocking the power of tumor tissue
September 2016
SHARING OPTIONS:

HAMBURG/MUNICH, Germany—Recently, Definiens and Indivumed GmbH formed a strategic partnership to offer a unique combination of tissue-based biomarker validation and assay development with Definiens Cognition Network Technology for image analysis and data mining.
 
This partnership will allow researchers and clinicians in oncology to benefit from a joint offering of Indivumed’s leading cancer database, Biobank, and analytical laboratory services for tissue analysis together with Definiens’ leading proprietary Cognition Network Technology and the Tissue Phenomics approach to oncology and diagnostics. Indiviumed specializes in stringent and highly standardized tissue collection processes that preserve biomolecules such as RNA and protein, allowing more accurate assessment of tissue patterns and more rigorous comparisons across samples.
 
“Customers of either company can now benefit from this partnership and our comprehensive approach for image analysis and tissue-based research and development in oncology,” said Hartmut Juhl, founder and CEO of Indivumed.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.